Increased Risk for Breast Cancer in Shift Workers Possibly Associated with Epigenetic Changes in Circadian Pathway

TON - March 2017, Vol 10, No 2 - Breast Cancer
Meg Barbor, MPH

Cape Town, South Africa—Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer (the World Health Organization’s source for information about cancer) has classified shift work as a possible carcinogen. However, according to researchers at the National Institute of Occupational Health in Oslo, Norway, and the Nofer Institute of Occupational Medicine in Lodz, Poland, the mechanisms of increased cancer risk caused by shift work are not fully understood.

Circadian disruption may affect epigenetic factors such as 5-methyl cytosine methylation in DNA. DNA hypermethylation is associated with increased cancer risk if it occurs in tumor suppressor genes, and some circadian genes are known to function as tumor suppressor genes. The re­searchers, led by Shan Zienolddiny from the National Institute of Occupational Health, hypothesized that these aberrant epigenetic modifications caused by circadian disruption may be involved in the development of breast cancer.

The team conducted a nested breast cancer case-control study of female nurses working night shifts and presented their results in a poster at the American Association for Cancer Research International Conference on New Frontiers in Cancer Research. Changes in methylation levels in a number of core circadian and melatonin receptor genes were analyzed in 352 patients with breast cancer and 355 healthy controls.

Significantly higher methylation in the MTNR1A gene was observed in patients with cancer than in controls, and PR-A methylation was significantly increased in night workers compared with day workers. Based on these data, the investigators concluded that changes in methylation status of the genes that regulate circadian rhythm may be associated with increased breast cancer risk in workers with consecutive night shifts. However, further research is needed on the effects of work schedules on epigenetic changes.—MB

Related Items
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Rebecca Bailey
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Breast Cancer, Immunotherapy
Strategies to Address the Long-Term Financial Burden of Cancer in Survivors
Meg Barbor, MPH
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Survivorship, Financial/Insurance Information
Fear of Recurrence in Cancer Survivors Different from Depression or Distress
Meg Barbor, MPH
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Survivorship, Financial/Insurance Information
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TON Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only, In the News
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+ News
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
The Challenges of Oral Cancer Drugs Use and Side-Effects Management
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Side-Effects Management, Drug Updates & News, ESMO
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Last modified: March 14, 2017